| Identification | Back Directory | [Name]
EPI-589 | [CAS]
1147883-03-1 | [Synonyms]
EPI-589
1,4-Cyclohexadiene-1-butanamide, α-hydroxy-α,2,4,5-tetramethyl-3,6-dioxo-, (αR)- | [Molecular Formula]
C14H19NO4 | [MDL Number]
MFCD34469558 | [MOL File]
1147883-03-1.mol | [Molecular Weight]
265.3 |
| Chemical Properties | Back Directory | [Boiling point ]
465.0±45.0 °C(Predicted) | [density ]
1.187±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
13.08±0.29(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
EPI-589, a quinone derivative, is a safe and well tolerated oxidoreductase enzyme inhibitor and a free radical scavenger, with blood-brain barrier permeable and orally available. EPI-589 is a redox-active neuroprotectant that effectively delays the symptoms of motor neuron disease in wobbler mice. EPI-589 can be used in amyotrophic lateral sclerosis (ALS) research[1][2][3][4]. | [in vivo]
EPI-589 exhibits a significant improvement in cerebrospinal fluid (CSF) and plasma-based biomarkers known to be associated with neuroinflammation and ALS disease progression[2]. | [References]
[1] Ng N, et al. Mitochondrial therapeutics and mitochondrial transfer for neurodegenerative diseases and aging. Neural Regen Res. 2025 Mar 1;20(3):794-796. DOI:10.4103/NRR.NRR-D-23-02106
[2] Matsumoto Y, et al. EPI-589, a redox-active neuroprotectant, potently protects cultured cells from oxidative stress and alleviates symptomatic and pathological progression of motor neuron disease in the wobbler mouse[J]. bioRxiv, 2022: 2022.03. 13.484182.
[3] Martinez A, et al. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis[J]. Expert opinion on investigational drugs, 2017, 26(4): 403-414.
[4] BioElectron’s EPI-589 Shows Positive Results in ALS Patients in Phase 2a Trial
[5] Phase IIa trial of EPI-589 in ALS shows improvement in CSF |
|
|